{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:06:33Z","timestamp":1784030793810,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,8]],"date-time":"2027-06-08T00:00:00Z","timestamp":1812412800000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K16369"],"award-info":[{"award-number":["JP22K16369"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019085","name":"Japanese Respiratory Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.resinv.2026.101459","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:55:27Z","timestamp":1780959327000},"page":"101459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics of autoantibodies neutralizing type I interferons in patients with coronavirus disease 2019 across phases of severe acute respiratory syndrome coronavirus 2 circulation"],"prefix":"10.1016","volume":"64","author":[{"given":"Haruka","family":"Sofuku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2506-4226","authenticated-orcid":false,"given":"Kenjiro","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-0320","authenticated-orcid":false,"given":"Katsuaki","family":"Asakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinari","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-8375","authenticated-orcid":false,"given":"Toshinori","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101459_bib1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1186\/s12879-021-06536-3","article-title":"Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients","volume":"21","author":"Dessie","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.resinv.2026.101459_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.resinv.2026.101459_bib4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41590-024-01815-y","article-title":"The ouroboros of autoimmunity","volume":"25","author":"Casanova","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10875-022-01252-2","article-title":"Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies","volume":"42","author":"Akbil","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib7","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200413119","article-title":"The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies","volume":"119","author":"Manry","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.resinv.2026.101459_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10875-024-01708-7","article-title":"Suppression of type I interferon signaling in myeloid cells by autoantibodies in severe COVID-19 patients","volume":"44","author":"Aoki","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s10875-022-01308-3","article-title":"Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19","volume":"42","author":"Eto","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012328","article-title":"Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis","volume":"8","author":"Relan","year":"2023","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.resinv.2026.101459_bib11","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251962","article-title":"Autoantibodies neutralizing type I IFNs in a fatal case of H5N1 avian influenza","volume":"223","author":"Zhang","year":"2026","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2026.101459_bib12","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230661","article-title":"Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in \u223c40% of patients","volume":"220","author":"Gervais","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2026.101459_bib13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s10875-021-01036-0","article-title":"Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain","volume":"41","author":"Troya","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10875-021-01203-3","article-title":"Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital","volume":"42","author":"Chauvineau-Grenier","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib15","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/art.39607","article-title":"Distinct functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2026.101459_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150867","article-title":"Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1","volume":"131","author":"Meisel","year":"2021","journal-title":"J Clin Investig"},{"key":"10.1016\/j.resinv.2026.101459_bib18","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2026.101459_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0014-5793(92)81523-O","article-title":"Soluble interferon-alpha receptor molecules are present in body fluids","volume":"314","author":"Novick","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1016\/j.resinv.2026.101459_bib20","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.4155\/bio.15.208","article-title":"Development and validation of an ELISA for quantification of soluble IFN-\u03b2 receptor: assessment in multiple sclerosis","volume":"7","author":"\u00d3rpez-Zafra","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.resinv.2026.101459_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abp8966","article-title":"Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs","volume":"8","author":"Bastard","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10875-024-01683-z","article-title":"Prevalence of neutralizing autoantibodies against type I interferon in a multicenter cohort of severe or critical COVID-19 cases in Shanghai","volume":"44","author":"Shi","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.resinv.2026.101459_bib23","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251760","article-title":"Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis","volume":"223","author":"Gervais","year":"2026","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2026.101459_bib24","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220514","article-title":"Autoantibodies against type I IFNs in patients with critical influenza pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J Exp Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:38:56Z","timestamp":1784029136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526000936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2212534526000936"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101459","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics of autoantibodies neutralizing type I interferons in patients with coronavirus disease 2019 across phases of severe acute respiratory syndrome coronavirus 2 circulation","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101459"}}